Receptos Announces Full Exercise of Underwriters' Option to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Receptos Announces Full Exercise of Underwriters' Option to Purchase Additional Shares and Completion of Underwritten Public Offering of Common Stock

SAN DIEGO, Nov. 24, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq: RCPT ), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced today the completion of the previously announced underwritten public offering of an aggregate of 4,140,000 shares of its common stock at a price to the public of $100.00 per share, which included 540,000 shares of its common stock sold pursuant to the full exercise of the option to purchase additional shares previously granted to the underwriters. The aggregate gross proceeds to Receptos from this offering were $414.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares of common stock in the offering were sold by Receptos.

Receptos intends to use the net proceeds received from this offering to fund continued development of its product candidate RPC1063 in ongoing and planned clinical trials for Relapsing Multiple Sclerosis, Ulcerative Colitis and Crohn's Disease, continued development of its in-licensed product candidate RPC4046 in an ongoing clinical trial for Eosinophilic Esophagitis, ongoing preclinical and research programs, and working capital and other general corporate purposes.

Credit Suisse Securities (USA) LLC and Leerink Partners LLC acted as joint lead book-running managers for the offering. Evercore Group L.L.C. and BMO Capital Markets Corp. acted as book-running managers. Wedbush PacGrow Life Sciences and Nomura Securities International, Inc. acted as co-managers.

The offering was made pursuant to a shelf registration statement on Form S-3 ASR that was filed by Receptos with the Securities and Exchange Commission (SEC) and became effective on July 16, 2014. The offering was made only by means of a prospectus supplement and an accompanying prospectus. Copies of the final prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering may be obtained from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, Telephone: (800) 221-1037, Email: newyork.prospectus@credit-suisse.com ; from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, Telephone: (800) 808-7525, Email: syndicate@leerink.com ; from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, New York, NY 10055, Telephone: (877) 993-2673, Email: ecm@evercore.com ; or from BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, Telephone: (800) 414-3627, Email: bmoprospectus@bmo.com .

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Receptos

Receptos is a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The Company's lead program, RPC1063, is a sphingosine 1-phosphate 1 receptor (S1P1R) small molecule modulator candidate for immune indications, including relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The Company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an allergic/immune-mediated orphan disease, eosinophilic esophagitis (EoE). Patents supporting RPC1063 were exclusively licensed to Receptos from The Scripps Research Institute (TSRI).

Forward Looking Statements

Statements contained in this release, other than statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  The words "expects," "believes," "anticipates," "may," "intends," "plans," "potential," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements do not constitute guarantees of future performance. Investors are cautioned that statements regarding the expected use of the net proceeds from the offering and the development and future potential of the Company's product candidates are forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include without limitation risks associated with market conditions, unexpected cash requirements and changes in the Company's business plan, and the process of discovering, developing and commercializing drug candidates that are safe and effective for use as human therapeutics. These and other risks regarding the Company's financial position and research and development programs are described in detail in the Company's SEC filings, including the Company's Annual Report on Form 10-K for the year ended December 31, 2013, the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 and the Registration Statement on Form S-3 ASR (File No. 333-197464) for the public offering. All forward-looking statements contained in this release speak only as of the date on which they were first made by the Company, and the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after such date.

Media and Investor Contact: Graham K. Cooper Chief Financial Officer, Receptos (858) 652-5708

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 62

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
America's Group Adds Swansea to Its UK Auction Map

Updated Category News Views 128

A Welsh Lane Joins a Larger Road Port Talbot just became a small but telling dot on America's Group's international map. The company has acquired Swansea Motor Vehicle Auction Limited, a long-standing South Wales wholesale and remarketing operation, and plans to run it under the G3 brand. This is not the sort of deal that makes markets levitate. It is the sort that tells...

Continue Reading
Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 56

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 0

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading
JOYY’s Ad Engine Gives Q3 Growth Some Real Teeth Now

Updated Category News Views 93

Three engines are finally pulling the cart at JOYY, and that is a far more interesting sight than another quarter of livestreaming merely holding together. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% sequentially. Those are sturdy numbers, especially for a business that investors have long tended to box in as...

Continue Reading
Replit Bets on Trusted Creators to Sell AI Agents at Work

Updated Category News Views 52

Forty-five creators may sound like a marketing footnote, but Replit is aiming at a real enterprise bottleneck: people do not buy grand AI slogans; they buy proof that a messy internal problem can actually get fixed. Its newly launched Replit & Co. program puts business and technology creators in front of that problem, with product access, demonstrations and direct contact...

Continue Reading
Term or Whole Life: Costs, Coverage, and Trade-Offs

Updated Category News Views 56

A life insurance choice can sit quietly in a drawer for years, then become brutally important at exactly the wrong moment. Laura Wood's November 18, 2026 comparison of term and whole life insurance is useful for that reason: it keeps dragging the conversation back to the unglamorous stuff that actually matters—how long coverage lasts, what it costs, and whether a...

Continue Reading
OCEG Faces China's Demographic Test After 40 Years

Updated Category News Views 83

A school group that once opened 35 kindergartens in a year is admitting the old playbook has run its course. That is the real message behind Oriental Cambridge Education Group's 40th-anniversary talk, not the balloons and ceremonial language. OCEG operates more than 170 institutions across 39 Chinese cities, and its chairman, Yu Yue, says the next chapter will be judged...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 58

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 133

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading

Top 5 Most Recently Viewed Articles

Proaction Secures $4.2M to Challenge Legacy Fleet Firms

Updated Category News Views 129

Fleet Management: A Market Ripe for Disruption You ever cruised past an old clunker of a business model and thought, "Now there's a setup ripe for a rethink"? That's exactly what Proaction's up to with their recent $4.2 million cash injection. For anyone keeping tabs on the legacy fleet management scene, it’s like watching someone take a claw hammer to a creaky old...

Continue Reading
Mission Bio Unveils Groundbreaking Solution for Genome Analysis

Updated Category News Views 161

Mission Bio dropped the bomb back in 2024 with its Tapestri Genome Integrity CNV Solution, a serious piece of kit aimed at transforming how researchers tackle genomic integrity. This ain't just another offering; it’s the first single-cell high-throughput solution that measures genome-wide copy number variations (CNVs). Think of it as a lifeline for those deep in...

Continue Reading
Varonis Shines as a Leader in Data Security Platforms

Updated Category News Views 286

Varonis Receives Prestigious Recognition in Data Security Varonis Systems, Inc. (Nasdaq: VRNS) is excited to receive acknowledgment as a Leader within the data security landscape, as highlighted by a prominent research firm in their latest report. This recognition emphasizes Varonis’ commitment to securing data effectively while continuously evolving their platform to...

Continue Reading
CocoFest 2025: Embracing Community and Wellness Together

Updated Category News Views 497

CocoFest 2025: A Celebration of Community and Wellness CocoFest is returning for its third rendition, bringing together people for a day dedicated to celebrating love and wellness. This exciting event will take place on a Saturday at the Boca Raton Innovation Campus, showcasing how love can enhance our lives in various ways. What to Expect at CocoFest 2025 The festival...

Continue Reading
Innovative Speech Therapy Game Enhances Learning for Kids

Updated Category News Views 169

Innovative Speech Therapy Game Revolutionizes Learning In a vibrant city, an inventive mind has crafted a special game designed to make speech therapy more engaging for children. This game, known as LINGUA TOKENS, aims to bring excitement into learning fundamental speech skills. With a focus on fun, children aged 4 to 9 can enhance their articulation through play-based...

Continue Reading